Bristol-Myers Drops Diabetes Drug
Posted on: Monday, 22 May 2006, 15:02 CDT
Bristol-Myers Squibb has discontinued the development of its type 2 diabetes candidate muraglitazar after the company decided further clinical trials to determine the safety of the drug were not worthwhile.
On October 18, 2005, the FDA issued an approvable letter for muraglitazar requesting additional information on the drug's cardiovascular safety profile. The company determined that in order to receive regulatory approval and to achieve commercial success for muraglitazar, further long-term studies to clarify the cardiovascular profile of the compound may be needed.
Since that time, Bristol-Myers Squibb has furthered its understanding of the compound and the regulatory path forward. This included additional analyses of existing studies with muraglitazar, results of outcomes studies with other PPAR alpha and gamma agonists, and the evaluation of the cardiovascular safety results from a recently-completed muraglitazar study. Based on these accumulated data, the company believes that a long-term trial is needed to achieve regulatory success.
"Based on this assessment, the company's commercial evaluation of other diabetes alternatives likely to be available in five years and consideration of competing development opportunities in the company's portfolio, Bristol-Myers Squibb has decided to discontinue the compound's development," the company said in a statement.
Source: Datamonitor
Related Articles
- Bristol-Myers Squibb and Pfizer Provide Update on Apixaban Clinical Development Program
- Bristol-Myers Squibb Selects Isis's Drug for Cardiovascular Disease Treatment
- Bristol-Myers Squibb and Imclone Systems Significantly Expand ERBITUX Clinical Development Program
- ImClone/Bristol-Myers: Seeking Regulatory Boost for Erbitux
- Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds
- Bristol-Myers Squibb and AstraZeneca Announce Worldwide Collaboration to Develop and Commercialize Diabetes Compounds
- Exelixis and Bristol-Myers Squibb Sign New Collaboration Agreement to Discover and Develop Novel Oncology Compounds
- Bristol-Myers Drug Raises Diabetes Risk: Study
- Bristol-Myers Squibb Statement on Muraglitazar, an Investigational Oral Treatment for Type 2 Diabetes
- Bristol-Myers Squibb and Merck Joint Statement on Regulatory Status of PARGLUVA(TM) (Muraglitazar), an Investigational Oral Treatment for Type 2 Diabetes
 |
 |
User Comments (0)
RSS Feeds